PUMA BIOTECHNOLOGY INC
PBYIPuma Biotechnology Inc. (PBYI) is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancer. Founded with the goal of creating innovative treatments, the company is known for its research and development efforts in oncology, particularly in the area of breast cancer. Puma Biotechnology's flagship product, neratinib, is an oral tyrosine kinase inhibitor approved for certain breast cancer indications. The company emphasizes advancing oncology therapies to improve patient outcomes through scientific innovation.
Company News
Er-Kim, an international pharmaceutical company, has signed an agreement with Puma Biotechnology to commercialize NERLYNX, a targeted therapy for early-stage HER2-positive breast cancer, in select countries in Eastern Europe and Central Asia.
Puma Biotechnology's Chief Commercial Officer, Jeffrey Jerome Ludwig, sold 2,598 shares of the company's common stock for over $9,600. The sale was part of a pre-arranged trading plan, and Ludwig's direct ownership in the company now stands at 118,388 shares.
Puma Biotechnology's Chief Commercial Officer Jeffrey Jerome Ludwig sold 6,051 shares worth over $19,000. The sale was executed under a pre-arranged trading plan. The company has reported a decrease in total and product revenue for Q1 2024, but is actively pursuing clinical trials and refining its distribution model.
Puma Biotechnology's Senior Vice President of Regulatory Affairs, Douglas M. Hunt, sold over $14,000 worth of company stock. The sale may attract attention from investors as it comes amid recent developments, including a decline in revenue but a strong gross profit margin.
Puma Biotechnology's CFO, Maximo F. Nougues, has sold shares worth over $17,000. The transaction was executed under a 10b5-1(c) trading plan, which allows insiders to sell shares on a predetermined schedule. The company has also been selected for inclusion in the Russell 3000 Index, which is expected to increase liquidity and exposure to institut...
